MyFinsight
Home
Blog
About
Contact
Download
Download image
Exercise of common stock
options for cash
$416K
Net cash provided by
(used in) financing...
$295K
Canceled cashflow
$121K
Net increase in
cash, cash...
-$321,029K
Canceled cashflow
$295K
Maturities of marketable
securities
$26,262K
Accounts payble
$10,685K
Stock-based compensation
$3,871K
Other non-current
assets
-$1,329K
Accrued professional
services
$880K
Balances due to and from
related parties
-$421K
Other accrued
liabilities
$305K
Amortization of right-of-use
assets
$112K
Depreciation of property and
equipment
$74K
Payment of deferred
transaction costs
$121K
Net cash (used in)
provided by investing...
-$285,407K
Net cash used in
operating activities
-$35,917K
Canceled cashflow
$26,262K
Canceled cashflow
$17,677K
Purchases of marketable
securities
$311,645K
Net loss
-$42,106K
Purchases of property and
equipment
$24K
Prepaid expense and
other currents assets
$7,531K
Accrued compensation
and benefits
-$3,729K
Operating lease
liabilities
-$123K
Net accretion of
premiums on marketable...
$74K
Accrued research and
development liabilities
-$31K
Back
Back
Cash Flow
BridgeBio Oncology Therapeutics, Inc. (BBOT)
BridgeBio Oncology Therapeutics, Inc. (BBOT)
source: myfinsight.com